Industry News

The latest news from the clinical trials industry.

News Powered By:

- a collaborative partner.


 


Lilly, Zymeworks expand collaboration agreement


CenterWatch News Online Headlines : October 24, 2014 8:10 am : Centerwatch

Eli Lilly and Zymeworks, a Vancouver-based, privately held biotherapeutics company, are expanding an existing licensing and collaboration agreement. Originally announced in January, the global strategic collaboration is focused on the development of an undisclosed number of novel bi-specific antibody therapeutics using Zymeworks’ proprietary Azymetric platform.



Celgene collaborates with Sutro Biopharma, inks option to acquire


CenterWatch News Online Headlines : October 24, 2014 8:09 am : Centerwatch

Sutro Biopharma, located in South San Francisco, has entered into a strategic collaboration and option agreement with Celgene to discover and develop multispecific antibodies and antibody drug conjugates (ADCs). This new agreement follows the December 2012 collaboration between the two companies and focuses on the field of immuno-oncology, while further broadening the Sutro platform for discovery, development and manufacture of best-in-class biotherapeutics.



J&J Innovation adds J-Labs incubator at Texas Medical Center


CenterWatch News Online Headlines : October 24, 2014 8:07 am : Centerwatch

Johnson & Johnson Innovation plans to expand J-Labs (formerly Janssen Labs) to include a new incubator located within Texas Medical Center’s new Innovation Institute. The 30,000-square-foot J-Labs facility will accommodate up to 50 life science startups.



Xiaflex approved for concurrent treatment in Dupuytren’s contracture patients


CenterWatch News Online Headlines : October 24, 2014 7:48 am : Centerwatch

Auxilium Pharmaceuticals has announced that the FDA has approved a supplemental Biologics Application (sBLA) for Xiaflex (collagenase clostridium histolyticum or CCH) for the treatment of up to two Dupuytren’s contracture (DC) joints in the same hand during a single treatment visit.



Treasury’s tax inversion changes scuttle some big biopharma mergers, modify others, prompting calls for Congressional corporate tax reform


CenterWatch News Online Headlines : October 23, 2014 10:50 am : Centerwatch

The widely-discussed $54.6 billion acquisition of Dublin-based Shire by AbbVie is officially canceled, having crumbled after a notice by the U.S. Treasury Department to tighten tax rules that deter U.S. companies from moving their legal headquarters to countries with lower business taxes.


« Page 1, 2, 3455, »